450 results match your criteria Dementia: Overview of Pharmacotherapy


Impact of COVID-19 on mental health in a Low and Middle-Income Country.

Cien Saude Colet 2020 Jun 25;25(suppl 1):2457-2460. Epub 2020 Apr 25.

Rede CoVida - Ciência, Informação e Solidariedade, Center of Data and Knowledge Integration for Health (CIDACS). R. Mundo 121/Parque Tecnológico do Edf. Tecnocentro/315, Trobogy. 41745-715 BA Salvador Brazil.

Mental disorders (MD) are commonly comorbid with cardiovascular, metabolic, and some infectious diseases. Since the current SARS-CoV-2 epidemic is affecting the most multimorbid individuals, we might expect that the epidemic will be particularly problematic for people with MD. Understanding the burden of an outbreak on mental health is fundamental to effective action towards containing the spread of the disease, as psychopathology might reduce endurance during the lockdown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/1413-81232020256.1.10932020DOI Listing

Overview of sleep disturbances and their management in Parkinson plus disorders.

J Neurol Sci 2020 May 8;415:116891. Epub 2020 May 8.

Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka 560029, India. Electronic address:

Sleep disturbance is one of the commonly reported non-motor symptoms in patients with Parkinson's disease (PD) as well as in Parkinson plus disorders such as multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS). Although there is a wealth of literature on sleep disturbances in PD, the same is not robust on the Parkinson plus disorders. This article aims to comprehensively review the sleep disturbances in Parkinson plus disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2020.116891DOI Listing

Cannabis for Symptom Management in Older Adults.

Med Clin North Am 2020 May;104(3):471-489

Research, Rocky Mountain Regional Veterans Affairs Medical Center, Denver-Seattle Center of Innovation, 1700 North Wheeling Street, Aurora, CO 80045, USA. Electronic address: https://twitter.com/Katie_Magid.

The purpose of this article is to present evidence on the efficacy and safety of medical cannabis as a therapy for symptom management in palliative care. This article provides an overview of the evidence on the risks and benefits of using medical cannabis for the indications of chronic pain, cancer-related pain, cancer cachexia, dementia, and Alzheimer's disease. Currently, there is insufficient evidence to determine the effectiveness and safety of cannabinoids for most reviewed indications, with the exception of chronic pain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mcna.2020.01.004DOI Listing

Small molecule targeting of SHIP1 and SHIP2.

Biochem Soc Trans 2020 02;48(1):291-300

Department of Chemistry, Syracuse University, Syracuse, NY, U.S.A.

Modulating the activity of the Src Homology 2 (SH2) - containing Inositol 5'-Phosphatase (SHIP) enzyme family with small molecule inhibitors provides a useful and unconventional method of influencing cell signaling in the PI3K pathway. The development of small molecules that selectively target one of the SHIP paralogs (SHIP1 or SHIP2) as well as inhibitors that simultaneously target both enzymes have provided promising data linking the phosphatase activity of the SHIP enzymes to disorders and disease states that are in dire need of new therapeutic targets. These include cancer, immunotherapy, diabetes, obesity, and Alzheimer's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1042/BST20190775DOI Listing
February 2020

An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.

Future Med Chem 2019 12;11(24):3179-3194

Laboratory of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Coimbra, 3000-548 Coimbra, Portugal.

A diverse range of -terminally truncated and modified forms of amyloid-β (Aβ) oligomers have been discovered in Alzheimer's disease brains, including the pyroglutamate-Aβ (AβpE). AβpE species are shown to be more neurotoxic when compared with the full-length Aβ peptide. Findings visibly suggest that glutaminyl cyclase (QC) catalyzed the generation of cerebral AβpE, and therapeutic effects are achieved by reducing its activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4155/fmc-2019-0163DOI Listing
December 2019
4.000 Impact Factor

Mitochondrial dysfunction and Alzheimer's disease: prospects for therapeutic intervention.

BMB Rep 2020 Jan;53(1):47-55

Convergence Research Center for Diagnosis, Treatment and Care System of Dementia, Korea Institute of Science and Technology, Seoul 02792; Division of Bio-Medical Science & Technology, KIST School, Korea University of Science and Technology, Seoul 02792, Korea.

Alzheimer's disease (AD) is a multifactorial neurodegenerative disease and has become a major socioeconomic issue in many developed countries. Currently available therapeutic agents for AD provide only symptomatic treatments, mainly because the complete mechanism of the AD pathogenesis is still unclear. Although several different hypotheses have been proposed, mitochondrial dysfunction has gathered interest because of its profound effect on brain bioenergetics and neuronal survival in the pathophysiology of AD. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999825PMC
January 2020

Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer's disease.

Expert Opin Ther Targets 2019 12 12;23(12):991-1004. Epub 2019 Dec 12.

Department of Psychiatry and Psychotherapy, Molecular Psychiatry, University Medical Center (UMG), Georg-August-University, Göttingen, Germany.

: Alzheimer's disease (AD) is characterized by a cerebral accumulation and aggregation of amyloid-β (Aβ) peptides, which mainly accumulate in the form of extracellular deposits. In addition to the well-described full-length peptides Aβ and Aβ, a variety of amino- and carboxy-terminally truncated Aβ variants have been identified in brain samples from sporadic and familial AD cases.: This review gives an overview on the role of truncated Aβ species in human AD, as well as in transgenic AD mouse models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14728222.2019.1702972DOI Listing
December 2019

Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.

Brain 2020 02;143(2):407-429

Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

Polyglutamine (polyQ) disorders are a group of nine neurodegenerative diseases that share a common genetic cause, which is an expansion of CAG repeats in the coding region of the causative genes that are otherwise unrelated. The trinucleotide expansion encodes for an expanded polyQ tract in the respective proteins, resulting in toxic gain-of-function and eventually in neurodegeneration. Currently, no disease-modifying therapies are available for this group of disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awz328DOI Listing
February 2020

Comorbid depression and apathy in HIV-associated neurocognitive disorders in the era of chronic HIV infection.

Handb Clin Neurol 2019 ;165:71-82

Neurology and HIV Departments, St. Vincent's Hospital, Sydney, NSW, Australia; Peter Duncan Neurosciences Unit, St. Vincent's Centre for Applied Medical Research, Sydney, NSW, Australia. Electronic address:

This chapter provides an overview of the current research on the question of depression and apathy in HIV-associated neurocognitive disorders (HAND) in the era of chronic HIV infection. After presenting the epidemiology of each condition showing that depression and apathy are the two most frequent psychiatric comorbidities of HAND, we review the current research, particularly in relation to the milder forms of HAND that characterize treated HIV cohorts. Doing so, we include findings on depression and apathy in non-HIV aging population and the risk of dementia, findings that are relevant to the aging HIV cohorts carrying a high burden of psychiatric comorbidities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-64012-3.00006-XDOI Listing

Frontotemporal dementia.

Handb Clin Neurol 2019 ;165:33-45

Cognitive and Behavior Research Unit, National Institute of Neurology and Neurosurgery, Havana, Cuba; Global Brain Health Institute, University of California, San Francisco, CA, United States.

Recent research reveals an overlap between frontotemporal dementia (FTD) and a variety of primary psychiatric disorders, challenging the artificial divisions between psychiatry and neurology. This chapter offers an overview of the clinical syndromes associated with FTD while describing links between these syndromes and neuroimaging. This is followed by a review of the neuropathology and genetic changes in the brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-64012-3.00003-4DOI Listing

The psychopharmacology of Huntington disease.

Handb Clin Neurol 2019 ;165:179-189

Department of Neurodegenerative Diseases and Gerontopsychiatry/Neurology, University of Bonn Medical Center, Bonn, Germany.

Huntington disease (HD) is a hereditary neurodegenerative disorder caused by an expanded cytosine-adenine-guanine triplet repeat in the huntingtin gene. The current diagnosis is based on the presence of typical motor signs in combination with a positive gene test. The motor onset of the disease is usually between 30 and 50 years of age, and the disease then progresses over around 20 more years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-64012-3.00010-1DOI Listing

Unlocking the concealed targets using system biology mapping for Alzheimer's disease.

Pharmacol Rep 2019 Dec 29;71(6):1104-1107. Epub 2019 Jun 29.

Solution Consultant, Clarivate Analytics, Bengaluru Karnataka, India.

Background: Alzheimer's disease (AD) constitutes a neural loss in histology of brain with involvement of complex genomic and environmental factors. Accumulation of amyloid beta (Aβ) peptide and phosphorylated tau are indicative of progression and cognitive decline. Hence an understanding of the underlying biological pathways and targets along with associated mechanisms would be useful for the development of improved therapeutics for treating AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharep.2019.06.012DOI Listing
December 2019
1 Read

Clinical drug development for dementia with Lewy bodies: past and present.

Expert Opin Investig Drugs 2019 Nov 28;28(11):951-965. Epub 2019 Oct 28.

Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.

: Dementia with Lewy bodies (DLB) is an under-researched area despite being the second most common type of degenerative dementia after Alzheimer's disease. It is an area of unmet need with no approved symptomatic or disease-modifying therapies. The pharmacological management of DLB is complex and challenging because early trials of drugs for DLB have resulted in no demonstrable efficacy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1681398DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823159PMC
November 2019
1 Read

A systematic overview of systematic reviews evaluating interventions addressing polypharmacy.

Am J Health Syst Pharm 2019 10;76(21):1777-1787

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

Purpose: To systematically evaluate and summarize evidence across multiple systematic reviews (SRs) examining interventions addressing polypharmacy.

Summary: MEDLINE, the Cochrane Database of Systematic Reviews, and the Database of Abstracts of Reviews of Effects (DARE) were searched for SRs evaluating interventions addressing polypharmacy in adults published from January 2004 to February 2017. Two authors independently screened, appraised, and extracted information. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ajhp/zxz196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170727PMC
October 2019

Antidiabetic therapies and Alzheimer disease.

Dialogues Clin Neurosci 2019 03;21(1):83-91

School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.

Given current lack of therapies for dementia, there is substantial interest in identifying potentially modifiable risk factors. Clarifying the potential of these factors to mitigate risk as well as determining the mechanisms that link these factors to dementia is expected to lead to new approaches for both preventing and treating neurodegenerative diseases such as Alzheimer disease. Modifiable factors include cardiovascular risks as well as related lifestyle-centric factors such as diet and physical activity (reviewed in this issue). Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780353PMC
March 2019
1 Read

Hydration Interventions for older people living in residential and nursing care homes: overview of the literature.

Br Med Bull 2019 09;131(1):71-79

Department of Nursing, Midwifery and Health, Northumbria University, Newcastle upon Tyne, UK.

Introduction: Care home populations experiencing high levels of multi-morbidity and dementia require support from caregivers to meet their hydration requirements. This article provides an overview of literature related to hydration interventions and highlights gaps in knowledge.

Sources Of Data: This paper draws on UK-focused literature from Applied Social Sciences Index and Abstracts (ASSIA), CINAHL, Medline, Proquest Hospital Premium Collection, Cochrane Library and RCN databases on hydration interventions for older people living with multi-morbidity and dementia in care homes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bmb/ldz027DOI Listing
September 2019

Targeting BDNF signaling by natural products: Novel synaptic repair therapeutics for neurodegeneration and behavior disorders.

Pharmacol Res 2019 10 20;148:104458. Epub 2019 Sep 20.

Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, 6734667149, Kermanshah, Iran.

Neurodegenerative disorders like Alzheimer's disease, Huntington's disease, Parkinson's disease, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia to prion diseases, Friedreich's ataxia, hereditary spastic paraplegia and optic atrophy type 1, and behavior disorders like neuropsychiatric, hyperactivity and autism spectrum disorders are closely associated with neurobiological deficits. Brain derived neurotrophic factor (BDNF) is an extensively studied neurotrophin. BDNF is essential for neuronal genesis, differentiation, survival, growth, plasticity, synaptic viability and transmission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2019.104458DOI Listing
October 2019
3 Reads

Cholinergic muscarinic M and M receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders.

Drug Discov Today 2019 12 6;24(12):2307-2314. Epub 2019 Sep 6.

Sosei Heptares, Cambridge, UK; Department of Psychiatry, University of Cambridge, Cambridge, UK; School of Psychological Sciences, Monash University, Melbourne, VIC, Australia. Electronic address:

Cholinergic dysfunction is involved in a range of neurological and psychiatric disorders, including schizophrenia, dementia and Lewy body disease (LBD), leading to widespread use of cholinergic therapies. However, such drugs have focused on increasing the availability of acetylcholine (ACh) generally, with relatively little work done on the muscarinic system and specific muscarinic receptor subtypes. In this review, we provide an overview of the major cholinergic pathways and cholinergic muscarinic receptors in the human brain and evidence for their dysfunction in several neurological and psychiatric disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.drudis.2019.08.009DOI Listing
December 2019
1 Read

[Prevention of cognitive decline and dementia by treatment of risk factors].

Nervenarzt 2019 Sep;90(9):921-925

Klinik für Psychiatrie und Psychotherapie, Uniklinik Köln, Medizinische Fakultät, Kerpener Straße 62, 50937, Köln, Deutschland.

Background: In Germany, approximately 1.6 million people are currently suffering from dementia. The prevalence of the disease is expected to double by 2060. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00115-019-0759-6DOI Listing
September 2019

Chorea.

Continuum (Minneap Minn) 2019 Aug;25(4):1001-1035

Purpose Of Review: This article provides an overview of the approach to chorea in clinical practice, beginning with a discussion of the phenomenologic features of chorea and how to differentiate it from other movement disorders. The diagnostic approach, clinical features of important acquired and genetic choreas, and therapeutic principles are also discussed. Practical clinical points and caveats are included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/CON.0000000000000763DOI Listing
August 2019
8 Reads

The Role of Dietary Supplements in Depression and Anxiety - A Narrative Review.

Pharmacopsychiatry 2019 Nov 8;52(6):261-279. Epub 2019 Jul 8.

LWL University Hospital for Psychiatry, Psychotherapy and Preventive Medicine, Bochum, Germany.

Introduction: Dietary supplements are very widely used in the general population and there is a growing market for them, which is against the recommendations of the German Society for Nutrition. There is some evidence that dietary supplements are useful additions in the treatment of psychiatric disorders. This review is an overview of available practical knowledge regarding the use of supplements in psychiatric treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0942-1875DOI Listing
November 2019
1 Read

Developments with multi-target drugs for Alzheimer's disease: an overview of the current discovery approaches.

Expert Opin Drug Discov 2019 09 5;14(9):879-891. Epub 2019 Jun 5.

a Department of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, Complutense University of Madrid , Madrid , Spain.

: Alzheimer's disease (AD), the most common type of dementia among older adults, is a chronic neurodegenerative pathology that causes a progressive loss of cognitive functioning with a decline of rational skills. It is well known that AD is multifactorial, so there are many different pharmacological targets that can be pursued. : The authors highlight the strategic value of privileged scaffolds in a multi-target lead compound generation against AD, exploring the concept of multi-target design, with a special emphasis on hybrid compounds. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2019.1623201DOI Listing
September 2019
33 Reads

Sneddon Syndrome: A Comprehensive Overview.

J Stroke Cerebrovasc Dis 2019 Aug 31;28(8):2098-2108. Epub 2019 May 31.

Neurology Section, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Sneddon syndrome (SS) is an episodic or chronic, slowly progressive disorder and characterized by generalized livedo racemosa (patchy, violaceous, skin discoloration) and recurrent cerebrovascular events. The histopathology of skin and brain is remarkable for a noninflammatory thrombotic vasculopathy involving medium- and small-sized dermal and cerebral arteries, respectively. Approximately 80% of the SS patients are women with a median age of diagnosis at 40 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2019.05.013DOI Listing
August 2019
11 Reads

[Drug treatment of Alzheimer's dementia : Status quo and perspectives].

Internist (Berl) 2019 Jul;60(7):761-768

AG Neuroprotektion, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Leipziger Str. 44, 39120, Magdeburg, Deutschland.

Alzheimer's disease (AD) is a neurodegenerative disease of the central nervous system. AD is characterized by progressive impairments of memory as well as other cognitive functions and an increasing loss of autonomy in everyday life. This review article provides an overview of the current state-of-the-art (symptomatic) pharmacological treatment of Alzheimer's disease, specifics in the context of concomitant neuropsychiatric symptoms in multimorbid patients, and drugs currently under development that have a potentially causal (disease modifying) effect are also mentioned. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00108-019-0625-4DOI Listing
July 2019
3 Reads

Overview of novel multifunctional agents based on conjugates of γ-carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes for treatment of Alzheimer's disease.

Chem Biol Interact 2019 Aug 14;308:224-234. Epub 2019 May 14.

Toxicology Program, Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI, 48109, USA; Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA; Center for Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, MI, 48109, USA. Electronic address:

Alzheimer's disease (AD) is a multifactorial neurodegenerative process whose effective treatment will require drugs that can act simultaneously on multiple pathogenic targets. Here, we present an overview of our previous multitarget studies of five groups of novel hybrid structures that combine, through spacers, five pharmacophores that have been found promising for AD treatment: γ-carbolines, carbazoles, tetrahydrocarbazoles, phenothiazines, and aminoadamantanes. Biological activity of the compounds was assessed by a battery of assays. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbi.2019.05.020DOI Listing
August 2019
4 Reads
2.577 Impact Factor

Recent Advances in Apoptosis: THE Role of Hydrazones.

Mini Rev Med Chem 2019 ;19(17):1427-1442

Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, Haydapaşa, 34668, İstanbul, Turkey.

The process of programmed cell death in higher eukaryotes (apoptosis), is generally characterized by distinct morphological characteristics and energy-dependent biochemical mechanisms. Apoptosis is considered as a vital component of various processes including normal cell turnover, proper development and functioning of the immune system, hormone-dependent atrophy, embryonic development and chemical-induced cell death. Apoptosis seems to play an important key role in the progression of several human diseases like Alzheimer's disease, Parkinson's disease and many types of cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389557519666190410125910DOI Listing
November 2019
2 Reads

An Overview of Primary Dementias as Clinicopathological Entities.

Authors:
Arash Salardini

Semin Neurol 2019 Apr 29;39(2):153-166. Epub 2019 Mar 29.

Department of Neurology, Yale School of Medicine, New Haven, Connecticut.

Dementia is a state of cognitive dysfunction which leads to functional decline. It is a syndrome caused by several medical and neurological causes, but most cases of dementia are due to "primary dementias." Primary dementias are neurological diseases whose manifestations are predominantly cognitive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1683445DOI Listing
April 2019
8 Reads

Role of "light therapy" among older adults with dementia: an overview and future perspectives.

Geriatr Psychol Neuropsychiatr Vieil 2019 Mar;17(1):83-91

Unité de psychologie de la sénescence, Université de Liège (ULiège), Belgique.

Given the relatively modest therapeutic benefits of drug treatments (and their associated costs) in dementia, there is a growing interest in non pharmacological approaches, including light therapy (light based therapy, LBT). Although various literature reviews exist, little attention has been given to the effects of these therapies (according to their modalities of application) on parameters related to both circadian rhythm and clinical parameters associated with dementia.

Aims: To provide an overview of available studies using LBT as non-pharmacological approach for managing persons with dementia and to make recommendations for its use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/pnv.2019.0786DOI Listing
March 2019
32 Reads

Can magnesium reduce central neurodegeneration in Alzheimer's disease? Basic evidences and research needs.

Neurochem Int 2019 06 22;126:195-202. Epub 2019 Mar 22.

Department of Neurology, CHUN Fann, Dakar, Senegal.

Magnesium (Mg) is a crucial divalent cation with more than 300 cellular functions. This ion shows therapeutic properties in several neurological diseases. Although there are numerous basic evidences showing that Mg can inhibit pathological processes involved in neuroglial degeneration, this low-cost option is not well-considered in clinical research and practice for now. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neuint.2019.03.014DOI Listing
June 2019
4 Reads

Pharmacological Interventions to Attenuate Alzheimer's Disease Progression: The Story So Far.

Curr Alzheimer Res 2019 ;16(3):261-277

Department of Pharmacology & Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

Alzheimer's disease (AD) is a progressive neurodegenerative disease and the most common cause of dementia in the elderly. Up to date, the available pharmacological options for AD are limited to cholinesterase inhibitors and memantine that may only provide modest symptomatic management with no significance in slowing down the disease progression. Over the past three decades, the increased interest in and the understanding of AD major pathological hallmarks have provided an insight into the mechanisms mediating its pathogenesis, which in turn introduced a number of hypotheses and novel targets for the treatment of AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1567205016666190301111120DOI Listing
June 2020
5 Reads

Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity.

Curr Protoc Pharmacol 2019 03 25;84(1):e57. Epub 2019 Feb 25.

Department of Biological Chemistry and Pharmacology, College of Medicine, Ohio State University, Columbus, Ohio.

The only drugs currently approved for the treatment of Alzheimer's Disease (AD) are four acetylcholinesterase inhibitors and the NMDA antagonist memantine. Apart from these drugs, which have minimal to no clinical benefit, the 40-year search for effective therapeutics to treat AD has resulted in a clinical failure rate of 100% not only for compounds that prevent brain amyloid deposition or remove existing amyloid plaques but also those acting by a variety of other putative disease-associated mechanisms. This indicates that the preclinical data generated from current AD targets to support the selection, optimization, and translation of new chemical entities (NCEs) and biologics to clinical trials is seriously compromised. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpph.57DOI Listing
March 2019
5 Reads

Concise Review: Modeling Neurodegenerative Diseases with Human Pluripotent Stem Cell-Derived Microglia.

Stem Cells 2019 06 10;37(6):724-730. Epub 2019 Mar 10.

Systems and Cell Biology of Neurodegeneration, IREM, University of Zurich, Schlieren, Switzerland.

Inflammation of the brain and the consequential immunological responses play pivotal roles in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and frontotemporal dementia (FTD). Microglia, the resident macrophage cells of the brain, have also emerged as key players in neuroinflammation. As primary human microglia from living subjects are normally not accessible to researchers, there is a pressing need for an alternative source of authentic human microglia which allows modeling of neurodegeneration in vitro. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/stem.2995DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6849818PMC
June 2019
30 Reads

Autophagy in Alzheimer's disease and promising modulatory effects of herbal medicine.

Exp Gerontol 2019 05 30;119:100-110. Epub 2019 Jan 30.

Integrated Chinese and Western Medicine postdoctoral research station, Jinan University, Guangzhou 510632, China; Shenzhen Institute of Geriatrics, Shenzhen 518020, China; The First Affiliated Hospital of Shenzhen University, Shenzhen 518035, China. Electronic address:

Alzheimer's disease (AD) is a progressive and unremitting neurodegenerative disorder characterized by memory loss and cognitive impairment. It affects the quality of life of victims severely. The prevalence of AD has been increasing in recent years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exger.2019.01.027DOI Listing
May 2019
4 Reads

New evolutions in the BACE1 inhibitor field from 2014 to 2018.

Bioorg Med Chem Lett 2019 03 4;29(6):761-777. Epub 2019 Jan 4.

Janssen Research & Development, Janssen Pharmaceutica N. V, Turnhoutseweg 30, B-2340 Beerse, Belgium.

β-Site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors offer the potential of disease-modifying treatment for Alzheimer's disease (AD). Since 2014, major breakthroughs have appeared in the field of BACE1 inhibitors. This review provides an overview of amidine-based BACE1 inhibitors between 2014 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2018.12.049DOI Listing
March 2019
2 Reads

Multidisciplinary approaches for targeting the secretase protein family as a therapeutic route for Alzheimer's disease.

Med Res Rev 2019 09 9;39(5):1730-1778. Epub 2019 Jan 9.

Faculty of Medical Technology, Center of Data Mining and Biomedical Informatics, Mahidol University, Bangkok, Thailand.

The continual increase of the aging population worldwide renders Alzheimer's disease (AD) a global prime concern. Several attempts have been focused on understanding the intricate complexity of the disease's development along with the on- andgoing search for novel therapeutic strategies. Incapability of existing AD drugs to effectively modulate the pathogenesis or to delay the progression of the disease leads to a shift in the paradigm of AD drug discovery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/med.21563DOI Listing
September 2019
6 Reads

Alzheimer's disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels.

J Pharmacol Sci 2019 Feb 18;139(2):51-58. Epub 2018 Dec 18.

Institute of Pharmacology and Toxicology and Biochemical Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

Low-threshold Ca spikes are mediated by T-type Ca channels, which have electrophysiological properties of fast inactivation and slow deactivation kinetics. A low membrane potential of approximately -60 mV is sufficient to trigger channel opening. We recently introduced a novel T-type Ca channel enhancer that improves cognition and inhibits amyloid beta aggregation in an Alzheimer's disease (AD) mouse model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jphs.2018.11.014DOI Listing
February 2019
8 Reads

Overview on the Effects of -Acetylcysteine in Neurodegenerative Diseases.

Molecules 2018 Dec 13;23(12). Epub 2018 Dec 13.

IRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy.

-acetylcysteine (NAC), which is an acetylated cysteine compound, has aroused scientific interest for decades due to its important medical applications. It also represents a nutritional supplement in the human diet. NAC is a glutathione precursor and shows antioxidant and anti-inflammatory activities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules23123305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320789PMC
December 2018
2 Reads

A vaccine against Alzheimer`s disease: anything left but faith?

Expert Opin Biol Ther 2019 01 17;19(1):73-78. Epub 2018 Dec 17.

a RIA Immunology, Department of BioMedical Research , University of Bern , Bern , Switzerland.

Introduction: Alzheimer's disease looms as a profound and growing threat to future human health. The disease is thought to be primarily driven by aberrant proteolysis of the amyloid precursor protein (APP) and amyloid beta (Aβ) plaque deposition.

Areas Covered: We provide an overview of the molecular pathology that leads to an increase in Aβ peptide accumulation, of the mechanism of action for antibody mediated therapies and of the therapeutic vaccines that target Aβ under development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14712598.2019.1554646DOI Listing
January 2019
19 Reads

Photosensitizing materials and platforms for light-triggered modulation of Alzheimer's β-amyloid self-assembly.

Biomaterials 2019 01 30;190-191:121-132. Epub 2018 Oct 30.

Department of Materials Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), 291, Daehak-ro, Yuseong-gu, Daejeon, 34141, Republic of Korea. Electronic address:

The abnormal aggregation of β-amyloid (Aβ) peptides is a hallmark of Alzheimer's disease (AD) that affects more than 10% of the people over the age 60 world-wide. While the exact mechanism of neuronal loss and cognitive decline has not been elucidated yet, the amyloid hypothesis about the causative role of Aβ aggregation in AD pathology has been widely supported by the numerous in vivo and in vitro data. In this respect, many efforts have been made to explore therapeutic agents that can modulate the aggregation of Aβ, but none of the efforts succeeded in producing effective anti-Aβ drugs for treating AD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2018.10.043DOI Listing
January 2019
10 Reads

WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.

Drug Resist Updat 2018 09 30;40:17-24. Epub 2018 Oct 30.

Department of Neurosurgery, Brain Tumor Center Amsterdam, Amsterdam University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HZ, Amsterdam, Netherlands. Electronic address:

Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall survival remains less than 15 months, during which extensive tumor infiltration throughout the brain occurs. The resulting metastasized cells in the brain are characterized by chemotherapy resistance and extensive intratumoral heterogeneity. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13687646183004
Publisher Site
http://dx.doi.org/10.1016/j.drup.2018.10.001DOI Listing
September 2018
36 Reads

PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.

Mol Neurobiol 2019 Jun 11;56(6):4306-4316. Epub 2018 Oct 11.

Aging Neuroscience Research Team, Tokyo Metropolitan Institute of Gerontology, Itabashi, Tokyo, 173-0015, Japan.

As the population of older individuals grows worldwide, researchers have increasingly focused their attention on identifying key molecular targets of age-related cognitive impairments, with the aim of developing possible therapeutic interventions. Two such molecules are the intracellular cyclic nucleotides, cAMP and cGMP. These second messengers mediate fundamental aspects of brain function relevant to memory, learning, and cognitive function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12035-018-1374-4DOI Listing
June 2019
2 Reads

[Atrial fibrillation as Risk Factor for Development of Cognitive Function Impairment and Dementia. Potential of Anticoagulant Therapy in Their Prevention].

Kardiologiia 2018 09;58(9):76-88

Medical Academy of Continuing Education.

This article presents an overview of data of Russian and foreign literature on possible associations between cognitive impairment and atrial fibrillation (AF). It includes modern classification of cognitive impairment, mechanisms of the effect of AF on cognitive functions and development of dementia, recommendations for the prevention of cognitive impairment in patients with AF. Special attention is paid to the assessment of cognitive status, and safe anticoagulant therapy, which is a priority in the prevention of cognitive impairment in patients with AF. Read More

View Article

Download full-text PDF

Source
September 2018
30 Reads

Mitochondrial therapeutic interventions in Alzheimer's disease.

J Neurol Sci 2018 12 28;395:62-70. Epub 2018 Sep 28.

Department of Bionano Technology, Gachon Bionano Research Institute, Gachon University, 1342 Sungnam-daero, Seongnam-si, Gyeonggi-do 461-701, South Korea. Electronic address:

Alzheimer's Disease (AD) is one of the most common age-related neurodegenerative diseases in the developed world. Treatment of AD is particularly challenging as the drug must overcome the blood brain barrier (BBB) before it can reach its target. Mitochondria are recognized as one of the most important targets for neurological drugs as the organelle is known to play a critical role in diverse cellular processes such as energy production and apoptosis regulation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2018.09.033DOI Listing
December 2018
6 Reads

Current approaches to the pharmacological treatment of Alzheimer's disease.

Aust J Gen Pract 2018 09;47(9):586-592

BPharm (Hons), PhD, NHMRC Dementia Leadership Fellow, Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Vic; NHMRC Cognitive Decline Partnership Centre, Hornsby Ku-ring-gai Hospital, Hornsby, NSW, Australia; School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA.

Background: Alzheimer's disease is the most common form of dementia and is a major contributor to morbidity and mortality in older Australians.

Objective: The aim of this article is to provide an overview of available pharmacological therapies for the symptomatic treatment of Alzheimer's disease.

Discussion: Acetylcholinesterase inhibitors (AChEIs) or memantine may be trialled in people with Alzheimer's disease to delay symptoms of cognitive and functional decline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31128/AJGP-05-18-4586DOI Listing
September 2018
1 Read

Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?

Neurotherapeutics 2018 10;15(4):1032-1035

International Centre for Neurotherapeutics, Dublin City University, 9, Dublin, Ireland.

While the extensive hunt for therapeutics combating Alzheimer's disease (AD) has fallen short of delivering effective treatments, breakthroughs towards understanding the disease mechanisms and identifying areas for future research have nevertheless been enabled. The majority of clinical trials with β- and γ-secretase modulators have been suspended from additional studies or terminated due to toxicity issues and health concerns. The lack of progress in developing innovative AD therapies has also prompted a resurgence of interest in more traditional symptomatic treatments with cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, as well as in the research of immune response modulators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-0668-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277284PMC
October 2018
5 Reads

Advances in the pharmacotherapeutic management of dementia with Lewy bodies.

Expert Opin Pharmacother 2018 10 13;19(15):1643-1653. Epub 2018 Sep 13.

a Department of Clinical and Experimental Medicine , Unit of Neurology, University of Pisa , Pisa , Italy.

Introduction: Dementia with Lewy bodies (DLB) is the second most common type of dementia in people over 65 years of age. Given the complex clinical phenotype, the management of DLB may be challenging, especially considering that there is limited evidence about specific interventions, and there are currently no Food and Drug Administration (FDA)/European Medicines Agency (EMA)-approved medications.

Areas Covered: This article provides an overview of the current pharmacotherapy in DLB and gives review to the most recent drug candidates in clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1519548DOI Listing
October 2018
5 Reads

Diagnostic challenges in rapidly progressive dementia.

Expert Rev Neurother 2018 10 17;18(10):761-772. Epub 2018 Sep 17.

a Clinical Dementia Center and National TSE Reference Center, Department of Neurology , Goettingen University Medical Center , Goettingen , Germany.

Introduction: Rapidly progressive dementia is a syndrome caused by numerous disease entities. Accurate diagnosis is crucial as substantial proportion of these diseases is highly treatable. Others might implicate specific hygienic problems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2018.1519397DOI Listing
October 2018
4 Reads

Phytotherapic use of the Crocus sativus L. (Saffron) and its potential applications: A brief overview.

Phytother Res 2018 Dec 22;32(12):2364-2375. Epub 2018 Aug 22.

Department of Pharmacy, G. d'Annunzio University, Chieti, Italy.

Crocus sativus L. (Saffron) has long been known for multiple target therapeutic uses. The plant metabolism is well investigated and the main metabolites related to saffron organoleptic qualities are crocin, crocetin, picrocrocin, and safranal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ptr.6181DOI Listing
December 2018
7 Reads

Perspective on Pimavanserin and the SAPS-PD: Novel Scale Development as a Means to FDA Approval.

Am J Geriatr Psychiatry 2018 10 14;26(10):1007-1011. Epub 2018 Jun 14.

VA Eastern Colorado Health Care System, Denver, CO.

In 2016, pimavanserin, a 5-hydroxytryptamine 2A inverse agonist, became the first U.S. Food and Drug Administration (FDA) approved medication for Parkinson disease psychosis (PDP) after demonstrating modest clinical improvement in a single positive trial as assessed by a novel PDP scale, the Scale for the Assessment of Positive Symptoms for Parkinson's Disease Psychosis (SAPS-PD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jagp.2018.06.001DOI Listing
October 2018
13 Reads

Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.

Adv Mater 2018 Nov 31;30(46):e1801362. Epub 2018 Jul 31.

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia.

Therapies directed toward the central nervous system remain difficult to translate into improved clinical outcomes. This is largely due to the blood-brain barrier (BBB), arguably the most tightly regulated interface in the human body, which routinely excludes most therapeutics. Advances in the engineering of nanomaterials and their application in biomedicine (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/adma.201801362DOI Listing
November 2018
96 Reads
17.493 Impact Factor